[Pharmacoeconomic analysis of gefitinib therapy in patients with non-cell cell lung cancer].
We performed a treatment efficacy analysis for non-small cell lung cancer (NSCLC) patients' population with EGFR mutation aimed at optimization of pharmacoeconomic factors. The employment of gefitinib leads to an increase in patients' life expectancy for a median of 1.05 years. The average cost-effectiveness of this therapy is 934.8 thousand rubles per additional year (903.9-1100.5 thousand rubles for each year). If gefitinib therapy is given only to patients with proved EGFR mutation it can decrease the average expenses by 211.6-251.8 thousand rubles per patient in comparison to undiagnosed patients's population receiving gefitinib without a decrease in clinical effect. Comparison of selective gefitinib administration with isolated chemotherapy (CT) yields an incremental cost-effectiveness ratio of 960.7 to 1010.0 thousand rubles per additional year. Therefore, the strategy of EGFR gene mutations testing in patients with inoperable NSCLC with consequent gefitinib therapy administration in patients positive for mutation lead to an increase in life expectancy and is characterized by acceptable cost-effectiveness.
S A
SA
Protsenko
A V
AV
Rudakova
F V
FV
Moiseenko
E V
EV
Levchenko
D E
DE
Matsko
A O
AO
Ivantsov
I I
II
Semënov
A G
AG
Ievleva
N V
NV
Mitiushkina
A V
AV
Togo
A V
AV
Novik
E N
EN
Imianitov
V M
VM
Moiseenko
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000191:economics* / Q000401:mortality; D003362:Cost-Benefit Analysis; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008017:Life Expectancy; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000191:economics* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011799:Quinazolines / Q000191:economics* / Q000627:therapeutic use*; D012426:Russia; D016019:Survival Analysis; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D011799:Quinazolines; D066246:ErbB Receptors; D000077156:Gefitinib